197 related articles for article (PubMed ID: 25439783)
1. The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells.
Hsu HS; Lin MH; Jang YH; Kuo TT; Liu CC; Cheng TH
J Thorac Cardiovasc Surg; 2015 Jan; 149(1):378-85. PubMed ID: 25439783
[TBL] [Abstract][Full Text] [Related]
2. What the Human Genome Project hasn't told us: the epigenetics of development of esophageal squamous cell cancer.
Ferraris VA
J Thorac Cardiovasc Surg; 2015 Jan; 149(1):386-7. PubMed ID: 25524691
[No Abstract] [Full Text] [Related]
3. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer.
Salehi Z; Mashayekhi F
Clin Biochem; 2006 Apr; 39(4):404-9. PubMed ID: 16375881
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.
Batool A; Majeed ST; Aashaq S; Majeed R; Shah G; Nazir N; Andrabi KI
Int J Biol Macromol; 2019 Mar; 125():651-659. PubMed ID: 30552925
[TBL] [Abstract][Full Text] [Related]
7. PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.
Yu L; Shang ZF; Wang J; Wang H; Huang F; Zhang Z; Wang Y; Zhou J; Li S
Oncotarget; 2015 Aug; 6(24):20356-69. PubMed ID: 26011939
[TBL] [Abstract][Full Text] [Related]
8. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.
Pons B; Peg V; Vázquez-Sánchez MA; López-Vicente L; Argelaguet E; Coch L; Martínez A; Hernández-Losa J; Armengol G; Ramon Y Cajal S
Int J Oncol; 2011 Nov; 39(5):1337-45. PubMed ID: 21750861
[TBL] [Abstract][Full Text] [Related]
9. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.
Soni A; Akcakanat A; Singh G; Luyimbazi D; Zheng Y; Kim D; Gonzalez-Angulo A; Meric-Bernstam F
Mol Cancer Ther; 2008 Jul; 7(7):1782-8. PubMed ID: 18644990
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
[TBL] [Abstract][Full Text] [Related]
11. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
Dumstorf CA; Konicek BW; McNulty AM; Parsons SH; Furic L; Sonenberg N; Graff JR
Mol Cancer Ther; 2010 Dec; 9(12):3158-63. PubMed ID: 20971826
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin-resistant phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in v-SRC-transformed hamster fibroblasts.
Tuhácková Z; Sovová V; Sloncová E; Proud CG
Int J Cancer; 1999 Jun; 81(6):963-9. PubMed ID: 10362146
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation dynamics of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) is discordant with its potential to interact with eukaryotic initiation factor 4E (eIF4E).
Showkat M; Beigh MA; Bhat BB; Batool A; Andrabi KI
Cell Signal; 2014 Oct; 26(10):2117-21. PubMed ID: 24975846
[TBL] [Abstract][Full Text] [Related]
14. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
[TBL] [Abstract][Full Text] [Related]
15. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
16. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
[TBL] [Abstract][Full Text] [Related]
17. 4E-BP1, a multifactor regulated multifunctional protein.
Qin X; Jiang B; Zhang Y
Cell Cycle; 2016; 15(6):781-6. PubMed ID: 26901143
[TBL] [Abstract][Full Text] [Related]
18. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.
Dilling MB; Germain GS; Dudkin L; Jayaraman AL; Zhang X; Harwood FC; Houghton PJ
J Biol Chem; 2002 Apr; 277(16):13907-17. PubMed ID: 11847216
[TBL] [Abstract][Full Text] [Related]
19. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
